Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a poat on LinkedIn:
“I am pleased to share our new article led by Guillermo Villacampa and published in Cancer Treatment Reviews: “Endocrine-based strategies after CDK4/6 inhibitors in advanced HR+/HER2– breast cancer.”
In this work, we review the evidence available to guide treatment decisions once a tumor progresses on a CDK4/6 inhibitor, a situation that is becoming increasingly common in daily practice.
The analysis highlights the heterogeneity of post-CDK4/6i options and the importance of using clinical and genomic information to select the most appropriate endocrine-based strategy for each case.
In general, endocrine sensitivity after CDK4/6 inhibitor progression is generally limited, with most strategies offering only modest and short-lived benefit.
Thanks to all co-authors and colleagues who contributed to this effort. You can read the article here.”
Title: Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis
Authors: Alicia Escudero, Meritxell Bellet, Cristina Saura, Anna Aguilera, Andri Papakonstantinou, Pablo Tolosa, José Ángel García-Sáenz, Fernando Moreno, Alfonso López de Sá, Francesco Schettini, Elia Seguí, Marta Gonzalez-Rodriguez, Victor Navarro, Juan Manuel Ferrero-Cafiero, Xavier González, Cristina Hernando, Alexios Matikas, Aleix Prat, Mafalda Oliveira, Tomas Pascual, Guillermo Villacampa
Read the Full Article.
More posts about Aleix Prat on OncoDaily.
